Sandbox Reserved 1688
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
{{Gal4 practice page}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | {{Gal4 practice page}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
==RNA Dependent RNA Polymerase of Hepatitis C Virus== | ==RNA Dependent RNA Polymerase of Hepatitis C Virus== | ||
- | <StructureSection load=' | + | <StructureSection load='1c2p' size='340' side='right' caption='Hepatitis C RdRp' scene=''> |
Background Information – | Background Information – | ||
The Hepatitis C virus (HCV) causes the disease Hepatitis C which is an infection in the liver. An HCV infection can either result in an acute infection or a chronic infection. Acute Hepatitis infections are most commonly asymptomatic and usually do not lead to a life-threatening condition. About 30% of acute infections are cured by the host without treatment in as little as six months. The infection, in the short term, causes yellow discoloration of the skin and eyes, referred to as jaundice. Multiple other symptoms are caused by Hepatitis C infection such as weight loss/loss of appetite, fatigue, spiderlike blood vessels, and various other symptoms. The remaining 70% of HCV infections result in a chronic infection. Long term symptoms or conditions caused by Hepatitis C commonly can lead to liver cirrhosis and liver cancer. In 2019 there were approximately 290,000 deaths due to a Hepatitis C infection. The majority of these deaths were largely due to the long-term adverse effects like, cirrhosis and liver cancer. Currently in the world, about 58 million people are chronically infected with the Hepatitis C virus and there are about 1.5 million new infections annually. In the United States, data estimates that 2.4 million people are infected with Hepatitis C. Due to the low percentage of diagnoses and the frequency of acute infection, it is believed that the number of Hepatitis C infections can range anywhere from 2.5 million to 4.7 million infected individuals. Currently, antiviral medicine can cure approximately 95% of HCV infected people, but lack of access to treatment and diagnosis is a major contributing factor to the prevalence of the disease. The antiviral medicine found most successful is termed Direct Acting Antivirals (DAAs). DAAs currently used in treatment include sofosbuvir and dasabuvir, while beclabuvir is currently in phase III clinical trials. The DAAs include nucleoside analogs that are similar to the natural substrate, but instead are phosphorylated before binding and lead to chain termination. Other antiviral medicines include non-nucleoside inhibitors (NNIs) that bind to allosteric sites and inhibit enzymatic activity. HCV is composed of a single-stranded, positive piece RNA. Due to HCV being a positive stranded RNA, it can function as mRNA and be immediately translated into viral proteins. | The Hepatitis C virus (HCV) causes the disease Hepatitis C which is an infection in the liver. An HCV infection can either result in an acute infection or a chronic infection. Acute Hepatitis infections are most commonly asymptomatic and usually do not lead to a life-threatening condition. About 30% of acute infections are cured by the host without treatment in as little as six months. The infection, in the short term, causes yellow discoloration of the skin and eyes, referred to as jaundice. Multiple other symptoms are caused by Hepatitis C infection such as weight loss/loss of appetite, fatigue, spiderlike blood vessels, and various other symptoms. The remaining 70% of HCV infections result in a chronic infection. Long term symptoms or conditions caused by Hepatitis C commonly can lead to liver cirrhosis and liver cancer. In 2019 there were approximately 290,000 deaths due to a Hepatitis C infection. The majority of these deaths were largely due to the long-term adverse effects like, cirrhosis and liver cancer. Currently in the world, about 58 million people are chronically infected with the Hepatitis C virus and there are about 1.5 million new infections annually. In the United States, data estimates that 2.4 million people are infected with Hepatitis C. Due to the low percentage of diagnoses and the frequency of acute infection, it is believed that the number of Hepatitis C infections can range anywhere from 2.5 million to 4.7 million infected individuals. Currently, antiviral medicine can cure approximately 95% of HCV infected people, but lack of access to treatment and diagnosis is a major contributing factor to the prevalence of the disease. The antiviral medicine found most successful is termed Direct Acting Antivirals (DAAs). DAAs currently used in treatment include sofosbuvir and dasabuvir, while beclabuvir is currently in phase III clinical trials. The DAAs include nucleoside analogs that are similar to the natural substrate, but instead are phosphorylated before binding and lead to chain termination. Other antiviral medicines include non-nucleoside inhibitors (NNIs) that bind to allosteric sites and inhibit enzymatic activity. HCV is composed of a single-stranded, positive piece RNA. Due to HCV being a positive stranded RNA, it can function as mRNA and be immediately translated into viral proteins. |
Revision as of 12:48, 7 October 2021
This Sandbox is Reserved from 09/01/2021 through 12/01/2021 for use in Che 462 taught by Ann Taylor at Wabash College, Crawfordsville, IN USA. This reservation includes Sandbox Reserved 1683 through Sandbox Reserved 1689. |
To get started:
More help: Help:Editing |
RNA Dependent RNA Polymerase of Hepatitis C Virus
|
References
https://www.cdc.gov/hepatitis/hcv/index.htm https://www.who.int/news-room/fact-sheets/detail/hepatitis-c https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/data-and-trends/index.html#1 https://www.hepatitisc.uw.edu/biology/structure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517137/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC23895/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514640/ https://www.frontiersin.org/articles/10.3389/fmicb.2019.01945/full#B45 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850383/